5-Hexadecyl-1.2.3.4-tetrazol | 898-37-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Hexadecyl-1.2.3.4-tetrazol
• 英文别名: 5-hexadecyl-1(2)H-tetrazole；5-hexadecyl-2H-tetrazole
• CAS: 898-37-3
• 化学式: C₁₇H₃₄N₄
• 分子量: 294.484
• InChiKey: GGLNYHIYYBKHPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Growth Hormones with Prolonged In-Vivo Efficacy
  申请人：Novo Nordisk HealthCare AG

  公开号：US20180221501A1

  公开（公告）日：2018-08-09

  The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

  本发明涉及优化了亚皮下注射的多肽化合物，例如具有连接剂的生长激素偶联物，该连接剂提供与白蛋白的非共价结合。
• Peptides for Use in the Treatment of Obesity
  申请人：Sensfuss Ulrich

  公开号：US20100016238A1

  公开（公告）日：2010-01-21

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其在调节一种或多种黑素皮质素受体类型方面具有有效性，以及该化合物在治疗中的使用，包括将该化合物用于需要该化合物的患者的治疗方法，以及将该化合物用于制造药物。该发明的化合物在与肥胖相关的多种疾病或病况的治疗方面具有特别的兴趣。
• Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
  申请人：Wulff Birgitte Schjellerup

  公开号：US20100022446A1

  公开（公告）日：2010-01-28

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其能有效调节一个或多个黑色素皮质素受体类型，并且涉及使用这些化合物进行治疗的方法，包括将这些化合物用于需要治疗的患者的治疗方法以及将这些化合物用于制造药物。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面具有特别的兴趣。
• Growth Hormones With Prolonged In-Vivo Efficacy
  申请人：Behrens Carsten

  公开号：US20120309944A1

  公开（公告）日：2012-12-06

  The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.

  本发明涉及具有持续作用的生长激素化合物。通过将一种结合白蛋白残基的氢亲和性间隔物与生长激素变体连接，实现了该效果。此外，还描述了制备和使用这些化合物的方法。这些生长激素化合物基于其改变的特征，被认为在治疗中特别有用。
• Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
  申请人：Epitracker, Inc.

  公开号：US10792266B2

  公开（公告）日：2020-10-06

  Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.

  提供了包含脂肪酸类似物的组合物，用于治疗代谢综合征、贫血、癌症、心血管疾病、糖尿病、血脂异常、高血压、炎症、胰岛素抵抗、糖尿病前期、脂肪肝、脂肪性肝炎、铁超载、神经退行性疾病（包括阿尔茨海默病和其他形式的痴呆症）以及其他相关疾病。还提供了诊断和监测代谢综合征和其他疾病的方法。